Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer
- Authors
- Kim, Young Saing; Park, Se Hoon; Kyung, Sun Young; Sym, Sun Jin; Lee, Sang Pyo; Park, Jeong Woong; Jung, Sung Hwan; Park, Jinny; Cho, Eun Kyung; Lee, Jae Hoon; Shin, Dong Bok
- Issue Date
- Mar-2011
- Publisher
- Humana Press, Inc.
- Keywords
- Small-cell lung cancer; Chemotherapy; Irinotecan; Carboplatin
- Citation
- Medical Oncology, v.28, no.1, pp 342 - 350
- Pages
- 9
- Indexed
- SCIE
SCOPUS
- Journal Title
- Medical Oncology
- Volume
- 28
- Number
- 1
- Start Page
- 342
- End Page
- 350
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/65349
- DOI
- 10.1007/s12032-010-9453-z
- ISSN
- 1357-0560
1559-131X
- Abstract
- This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m(2) on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4 weeks. Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival (OS) were 5.6 and 8.7 months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3-4 neutropenia occurred in 30% of the patients and 7% of patients presented with febrile neutropenia. Grade 3-4 diarrhea occurred in 21% of the patients. A subgroup consisting of patients a parts per thousand yen65 years of age had outcomes similar to the younger group < 65 years of age. The objective RR was 72% in the patients < 65 years of age and 77% in the patients a parts per thousand yen65 years of age (P = .738). The median PFS and OS (< 65 years vs. a parts per thousand yen65 years) were 5.3 vs. 5.6 months (P = .835) and 9.0 vs. 8.7 months (P = .648), respectively. The combination of irinotecan and carboplatin is active and tolerable in patients with ED-SCLC. This regimen could be considered as a treatment option for patients of advanced age.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 5. Others > ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.